Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEFFREY RIES

NPI
1780647735
CMS profile
217123
Location
UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$1,254.06

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $941.71 4
Food and Beverage $312.35 5

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Boehringer Ingelheim Pharmaceuticals, Inc. $1,254.06 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEFFREY RIES

NPI 1780647735 · CMS profile ID 217123

UPLAND, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1780647735?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEFFREY RIES, NPI 1780647735, CMS profile ID 217123. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1780647735?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEFFREY RIES, NPI 1780647735, CMS profile ID 217123. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1780647735?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEFFREY RIES, NPI 1780647735, CMS profile ID 217123, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1780647735?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $1,254.06 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $39.6611/27/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155218028 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $39.6611/27/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155218030 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $49.5811/27/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155218032 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $49.5811/27/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155218034 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $133.8711/27/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155218038 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $242.5911/27/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155218040 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $36.1810/25/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155217982 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $66.5210/25/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155218036 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $596.4210/15/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155218042 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $64.23 2
PY2022 $1,872.84 11
PY2024 $1,254.06 9

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,063.51 9
PY2025 Principal investigator $206,042.38 82
PY2024 Principal investigator $233,005.53 42
PY2023 Recipient $4,662.00 3
PY2023 Principal investigator $237,413.37 35
PY2022 Principal investigator $275,295.64 21
PY2021 Principal investigator $31,781.00 3
PY2020 Recipient $2,280.12 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

91 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient ABBVIE INC. $24.99 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400760
Recipient ABBVIE INC. $70.00 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400765
Recipient ABBVIE INC. $396.44 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400768
Recipient ABBVIE INC. $60.00 12/09/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400772
Recipient ABBVIE INC. $70.00 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400739
Recipient ABBVIE INC. $132.85 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400743
Recipient ABBVIE INC. $235.25 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400747
Recipient ABBVIE INC. $24.99 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400751
Recipient ABBVIE INC. $48.99 12/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202400756
Principal investigator 1 ABBVIE INC. $760.50 11/04/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202521097
Principal investigator 1 Axsome Therapeutics, Inc. $2,045.44 10/17/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915704
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,500.00 10/10/2025 Non-covered Recipient Entity
Management Group LLC Pacific Clinical Research
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220804134
Principal investigator 1 ABBVIE INC. $306.80 10/09/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202514307
Principal investigator 1 Axsome Therapeutics, Inc. $7,858.90 09/15/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915702
Principal investigator 1 ABBVIE INC. $2,667.60 09/03/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202507471
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $690.00 08/15/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223284309
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,070.00 08/15/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223284311
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,380.00 08/15/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223284313
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,644.22 08/11/2025 Non-covered Recipient Entity
Management Group LLC Pacific Clinical Research
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220804130
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,518.00 08/08/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283965
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,605.00 08/08/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223283967
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,186.20 08/07/2025 Non-covered Recipient Entity
Management Group LLC Pacific Clinical Research
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220804132
Principal investigator 1 ABBVIE INC. $422.50 08/05/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202501682
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679666
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 08/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679668
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 08/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679670
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 08/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679672
Principal investigator 1 Axsome Therapeutics, Inc. $3,522.13 07/23/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915676
Principal investigator 1 ABBVIE INC. $2,356.90 07/02/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202494943
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679674
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679676
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679678
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 07/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679680
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 07/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679682
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 07/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679684
Principal investigator 1 Axsome Therapeutics, Inc. $7,006.81 06/13/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915674
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 06/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679656
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679658
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679660
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679662
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679664
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,040.00 05/28/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
A LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF TAK-861 IN PARTICIPANTS WITH SELECTED CENTRAL HYPERSOMNIA CONDITIONS No dispute reported 06/30/2026 1223280484
Principal investigator 1 Axsome Therapeutics, Inc. $9,196.46 05/16/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915672
Principal investigator 1 PFIZER INC. $52.00 05/08/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228851943
Principal investigator 1 ABBVIE INC. $422.50 05/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202482083
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 05/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679646
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679648
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679650
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679652
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679654
Principal investigator 1 PFIZER INC. $436.00 04/17/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228852033
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $95.12 04/08/2025 Non-covered Recipient Entity
Management Group LLC Pacific Clinical Research
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220804128
Principal investigator 1 ABBVIE INC. $422.50 04/03/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202470431
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679636
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679638
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679640
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679642
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 04/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679644
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,272.00 03/28/2025 Non-covered Recipient Entity
Management Group LLC Pacific Clinical Research
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220804126
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,070.00 03/26/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223277035
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,750.00 03/21/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223276931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,660.00 03/21/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy No dispute reported 06/30/2026 1223276933
Principal investigator 1 ABBVIE INC. $2,243.80 03/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202457304
Principal investigator 1 ABBVIE INC. $3,300.00 03/06/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202457315
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679616
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679618
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679620
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679622
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 03/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679624
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $98,518.00 03/01/2025 Non-covered Recipient Entity
Management Group LLC Pacific Clinical Research
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220804124
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 02/25/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679628
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 02/25/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679630
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 02/25/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679632
Principal investigator 1 ABBVIE INC. $422.50 02/05/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202445742
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679606
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679608
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679610
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679612
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679614
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 01/27/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679626
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,500.00 01/23/2025 Non-covered Recipient Entity
Management Group LLC Pacific Clinical Research
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220804122
Principal investigator 1 PFIZER INC. $4,983.30 01/23/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228852947
Principal investigator 1 Axsome Therapeutics, Inc. $1,421.25 01/14/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915668
Principal investigator 1 Axsome Therapeutics, Inc. $505.87 01/14/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199915670
Principal investigator 1 ABBVIE INC. $2,356.90 01/02/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202435708
Principal investigator 1 ABBVIE INC. $1,891.50 01/02/2025 Non-covered Recipient Entity
PACIFIC CLINICAL RESEARCH MANAGEMENT GROUP LLC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202435711
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679598
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679600
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679602
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679604
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Pacific Clinical Research Management Group
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220679634